Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recibokibart Long-Term Extension in Generalized Pustular Psoriasis
NCT06477536Phase 3Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of HB0034 in generalized pustular psoriasis (GPP), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2024; status: recruiting.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT06477536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477536.